



**RADIOMOLECULAR
PRECISION
ONCOLOGY**
FOR PATIENTS WORLDWIDE

THE ICPO FOUNDATION

ICPO THERANOSTICS VIRTUAL SUMMIT 2026 PRELIMINARY PROGRAMME (Feb 2026) NOVEMBER 12 & 13, 2026

CHAIRS



**Prof. Richard P.
Baum**



**Prof. Frederik L.
Giesel**



**Prof. Rudolf
A. Werner**

World-class programme:

Strong on multidisciplinary exchanges and patient focus covering 5 themes:

- Rising stars in Theranostics - Beyond PSMA and FAP
- Growing space of Alphas - Outlook on untapped potential
- Clinical trials planning - Navigate from hurdles to outcomes
- Leveraging AI in Theranostics - Advancing clinical practice globally
- Recommendations to grow patient access to Theranostics innovation over the next 5 years

MODERATORS



**Odile Jaume
CEO**



**Susanne Simon
Head of Communications**

**Pre-Register here:
www.icpo.foundation**





Day 1 - Nov 12, 2026 (CET)	Adopting new radiopharmaceuticals at your Theranostics center
2:00 - 2:15 pm	Welcome - U.J. Vetter & O. Jaume Programme overview by Chairs - R. Baum, F. Giesel, R. Werner Keynote introduction – S. Simon
2:15 - 2:35 pm	KEYNOTE: From Imaging to Cure: Theranostics as a Core Pillar in Today's Oncology Toolbox – M. Hofman
2:35 - 3:25 pm	SESSION I: Outlook into Next Gen emitters - From Y-90 DOTATOC to Modern PRRT: A 30-Year Journey in NET Treatment – Richard P. Baum - - Selection of optimal radionuclide: Efficacy and safety of Tb161 versus Lu177 – C. Mueller - Clinical potential of Tb161 for radioligand therapy – D. Wild
3:25 - 4:15 pm	SESSION II: Clinical trends in Alpha corner - Ac225 insights in latest trials – M. Sathekge - Latest clinical advances in Astatine (At211): T. Watabe - Novel development and dosing strategies for alpha therapies, ADVC001 (Pb212) experience – A. Karmann - Pb212 beyond prostate cancer – M. Schultz
4:15 - 4:40 pm	PANEL 1: Alpha only approach: Potential & effectiveness? Benchmark with combination therapies? Moderators: F. Giesel and R. Werner
4:40 - 4:50 pm	BREAK
4:50 - 5:40 pm	SESSION III: Sunrise of FAP & other compounds on the horizon - FAP-based radiotheranostics for the treatment of diverse adenocarcinomas and sarcomas – E. Perrone - 3rd Generation of PSMA – S. Rowe - Novel targets incl. CAIX, PL1 and others – M. Murakami
5:40 - 6:30 pm	SESSION IV: Will “big” or “small” shape the future? What space for pre-targeting? - Perspective from radiopharmaceutical innovation – J. Cardinale - Perspective from clinical radiochemistry – J. Lewis - Perspective from translational nuclear medicine – S. Lütje
6:30 - 6:55 pm	PANEL 2: Is FAP revolutionary in terms of patient outcomes? Will it become the new gold standard for all Theranostics centers? Moderators: R. Baum and F. Giesel
6:55 - 7:00 pm	Wrap up and Closing of Day 1 Day 1 Impressions from R. Baum, F. Giesel, R. Werner Closing - O. Jaume & S. Simon

ICPO THERANOSTICS VIRTUAL SUMMIT 2026

NOVEMBER 12 & 13, 2026



GROWING PATIENT ACCESS: ADOPTING NEW RADIOPHARMACEUTICALS THERAPIES AND PLANNING FOR CLINICAL TRIALS

Day 2 – Nov 13, 2026 (CET)	Planning and navigating clinical trials at your Theranostics center
10:00-10:05 am	Welcome - O. Jaume Programme overview by Chairs R. Baum, F. Giesel and R. Werner Keynote introduction – S. Simon
10:05-10:25 am	KEYNOTE: Future outlook into radiotheranostics - K. Herrmann
10:25-11:15 am	SESSION V: Planning your clinical trial - Current and future design of theranostics clinical trials – I. Rakovic - Structuring & managing trial data – S. Vohra - Listening to patients advocates on clinical trials – E. Briers
11:15-12:00 am	SESSION VI: Navigating trial design involving novel approaches - First use of Rh188-PSMA, as Tc99m-PSMA companion: M. Sathekge - uPAR-targeted PET imaging in oncology research – A. Kjaer - Role of Genomics & Transcriptomics or when in vitro meets in vivo – R. Wirtz
12:00-12:25 am	PANEL 3: Lessons learned for a Theranostics center head: Success factors and attention points Moderators: F. Giesel and R. Werner
12:25-12:35 am	BREAK
12:35-1:25 pm	SESSION VII: How to reach and select patients for your trials? - Theranostics patient selection at large volume cancer center – D. Deandreis - Challenges and opportunities in patient recruitment for Theranostics in emerging research centers – C. Carreras - Leveraging Ancora.ai radiopharmaceuticals trial finder – D. Ralic
1:25-2:15 pm	SESSION VIII: Leveraging AI in Theranostics at your center - Leveraging AI to advance clinical Theranostics globally – J. Tran-Gia - Empowering AI in Clinical Trials - V. Prasad - ARCHE: An AI-driven Curation and Harmonization Engine for Structuring Multimodal Theranostics Data – L. Sundar
2:15-2:40 pm	PANEL 4 / FINAL ROUND TABLE: Essential recommendations to grow patient access to radiotheranostics innovation over the next 5 years? Moderators: R. Baum, F. Giesel and R. Werner
2:40-3:00 pm	Wrap up and closing of ICPO Summit 2026 Wrap up by Chairs R. Baum, F. Giesel and R. Werner Closing by O. Jaume and S. Simon